<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20171212037847N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-12-22</date_registration>
      <primary_sponsor>Isfahan University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effect of EMLA cream, lidocaine spray with and without aromatherapy with lavender on pain during Arterio-Venous Fistula (AVF)   cannulation among  patients undergoing hemodialysis</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of EMLA cream, lidocaine spray with and without aromatherapy with lavender on pain during Arterio-Venous Fistula (AVF)   cannulation among  patients undergoing hemodialysis</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-03-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/75198</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Other design features: There is no specific case, Randomization description: In this research, the researcher uses the easy sampling method, so that among the available samples, patients who meet the criteria for entering this study are selected so that the samples reach the desired number, and then the samples are divided into two groups. The form of random allocation is done using mini-pie software. After minimization software divides the samples among the groups in such a way that there is a minimum difference between them, thus homogenization of the samples is also done and the confounding variables are under control. The desired variables to enter the software include (age, sex, duration of fistula placement and duration of hemodialysis), Blinding description: In this research, the VAS scale is used as a criterion for measuring the pain level of patients. After being at the patient's bedside, the researcher assistant asked the patients to choose the intensity of their pain and draw a line around the desired number. Also, in the data analysis stage, the type of intervention and the intervention and control groups are not known.</study_design>
      <phase>3</phase>
      <hc_freetext>Chronic kidney disease, stage 5.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Intervention group: First, the patients are asked to express their experienced pain based on the visual analogue pain measurement scale in the first three sessions, immediately and 30 minutes after cannulation of the arteriovenous fistula using a routine method without intervention, and the data collected and recorded. Then, during cannulation, lidocaine spray, spelled cream or aromatherapy with lavender is used for all patients, or a combination of aromatherapy and lidocaine spray and a combination of aromatherapy and spelled cream. The duration of each intervention is 3 days. And there is a 48-hour cleaning period between interventions (patients are treated with hemodialysis three times a week, so there is a 48-hour cleaning period between sessions). It should be noted that the order and sequence of interventions is determined randomly for each patient. In this way, the names of 4 interventions are placed in 4 envelopes and the patients are asked to choose one of the envelopes randomly. choose, the first envelope is the first intervention that is done for the patient, then the patient is asked to choose one of the 3 envelopes, the second envelope that is chosen by the patient is the second intervention that is given to the patient Then the patient is asked to choose one of the remaining 2 envelopes, and thus the third intervention is determined, and the last remainingMethod of Spraying Lidocaine:In the lidocaine spray method, the skin is prepared initially and, then, the researcher sprays two puffs of 2% lidocaine (20 mg) onto the skin from a distance of 5 cm. After a five-minute interval, the skin surface around the fistula is disinfected using cotton pads soaked in 70% alcohol, and specialized hemodialysis needles are inserted into the veins of the fistula area by the nurse .Method of Using Emla Cream:For using Emla cream, two ml of Emla cream, based on the instructions for using the product, is applied 45 to 60 minutes before inserting the needle into the fistula and is fixed with a protective dressing. After 45 minutes, the Emla cream is removed from the skin and after disinfecting the area with cotton pads soaked in 70% alcohol, specialized hemodialysis needles are inserted in the veins of the fistula area by the nurse (9). Two minutes and 30 seconds after inserting the arterial needles, the pain intensity is measured by the nurse using a numerical pain intensity scale. To ensure that the previous intervention does not interfere, the interval between interventions is considered .Method of Using Lavender Aromatherapy:In this method, lavender oil is diluted with distilled water/sweet almond oil in a ratio of 1 to 10 (lavender oil 10% produced by Barij Essense Pharmaceutical Company)  and, then, three drops of diluted lavender oil is placed on a piece of cotton and the patient is asked to breathe slowly from a distance of 7 to 10 cm and inhale it for 5 minutesLavender oil is typically stored in dark glass bottles with tightly closed lids and is kept in a cool environment, ensuring that no essential oil properties are lost. To assess the long-term effects of lavender oil inhalation, three hemodialysis sessions are implemented per week, and lavender oil inhalation is performed before each hemodialysis session . envelope is the last intervention that will be performed for the patient. Intervention 2: Control group: In the non-intervention method, the arterial-venous hemodialysis needles are inserted into the fistula area by the nurse and, after finishing the work and fixing the needles, the pain is measured and its level felt by the patient during the insertion of the arterial-venous needles is marked and recorded. The level of pain is measured only the first time the nurse inserts any of the arterial or venous needles. If the needles are not initially placed correctly and the nurse needs to make another attempt by piercing the skin again, the patient's pain level will not be measured.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is In the consent form, the personal information of the patients remains confidential</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Maryam Sadat Hashemi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hezarjarib avenue,Isfahan,Iran.</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>009832253349</zip>
        <telephone>+98 913 411 8910</telephone>
        <email>Maryam.hashemi@nm.mui.ac.ir</email>
        <affiliation>Isfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Maryam Sadat Hashemi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hezarjarib avenue,Isfahan,Iran.</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>00988199875784</zip>
        <telephone>+98 913 411 8910</telephone>
        <email>Maryam.hashemi@nm.mui.ac.ir</email>
        <affiliation>Isfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Suffering from the final stage of chronic kidney disease
8 years old and older
Being under dialysis for more than 3 months
No participation in similar research programs at the same time
Being conscious
Being able to communicate verbally
Passage of 3 months after fistula creation and having an efficient fistula</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of addiction and smoking
Presence of skin  and vascular lesions in the involved limb
Allergy  to lidocaine, prilocaine, or other local anesthetics
Allergy to essential oils
History of asthma, bronchitis, and chronic respiratory diseases
Smell problems
Severe pain in other organs</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N18.5</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Chronic kidney disease, stage 5</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Intervention group: First, the patients are asked to express their experienced pain based on the visual analogue pain measurement scale in the first three sessions, immediately and 30 minutes after cannulation of the arteriovenous fistula using a routine method without intervention, and the data collected and recorded. Then, during cannulation, lidocaine spray, spelled cream or aromatherapy with lavender is used for all patients, or a combination of aromatherapy and lidocaine spray and a combination of aromatherapy and spelled cream. The duration of each intervention is 3 days. And there is a 48-hour cleaning period between interventions (patients are treated with hemodialysis three times a week, so there is a 48-hour cleaning period between sessions). It should be noted that the order and sequence of interventions is determined randomly for each patient. In this way, the names of 4 interventions are placed in 4 envelopes and the patients are asked to choose one of the envelopes randomly. choose, the first envelope is the first intervention that is done for the patient, then the patient is asked to choose one of the 3 envelopes, the second envelope that is chosen by the patient is the second intervention that is given to the patient Then the patient is asked to choose one of the remaining 2 envelopes, and thus the third intervention is determined, and the last remainingMethod of Spraying Lidocaine:In the lidocaine spray method, the skin is prepared initially and, then, the researcher sprays two puffs of 2% lidocaine (20 mg) onto the skin from a distance of 5 cm. After a five-minute interval, the skin surface around the fistula is disinfected using cotton pads soaked in 70% alcohol, and specialized hemodialysis needles are inserted into the veins of the fistula area by the nurse .Method of Using Emla Cream:For using Emla cream, two ml of Emla cream, based on the instructions for using the product, is applied 45 to 60 minutes before inserting the needle into the fistula and is fixed with a protective dressing. After 45 minutes, the Emla cream is removed from the skin and after disinfecting the area with cotton pads soaked in 70% alcohol, specialized hemodialysis needles are inserted in the veins of the fistula area by the nurse (9). Two minutes and 30 seconds after inserting the arterial needles, the pain intensity is measured by the nurse using a numerical pain intensity scale. To ensure that the previous intervention does not interfere, the interval between interventions is considered .Method of Using Lavender Aromatherapy:In this method, lavender oil is diluted with distilled water/sweet almond oil in a ratio of 1 to 10 (lavender oil 10% produced by Barij Essense Pharmaceutical Company)  and, then, three drops of diluted lavender oil is placed on a piece of cotton and the patient is asked to breathe slowly from a distance of 7 to 10 cm and inhale it for 5 minutesLavender oil is typically stored in dark glass bottles with tightly closed lids and is kept in a cool environment, ensuring that no essential oil properties are lost. To assess the long-term effects of lavender oil inhalation, three hemodialysis sessions are implemented per week, and lavender oil inhalation is performed before each hemodialysis session . envelope is the last intervention that will be performed for the patient.</i_keyword>
      <i_keyword>Control group: In the non-intervention method, the arterial-venous hemodialysis needles are inserted into the fistula area by the nurse and, after finishing the work and fixing the needles, the pain is measured and its level felt by the patient during the insertion of the arterial-venous needles is marked and recorded. The level of pain is measured only the first time the nurse inserts any of the arterial or venous needles. If the needles are not initially placed correctly and the nurse needs to make another attempt by piercing the skin again, the patient's pain level will not be measured.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain. Timepoint: In 2 occasions, immediately and half an hour after cannulation for 3 days. Method of measurement: Visual Analogue Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Comfort. Timepoint: immediately and half an hour after cannulation for 3 days. Method of measurement: Hemodialysis Comfort Scale.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Isfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-05-19</approval_date>
        <contact_name>Ethics committee of Isfahan  University of Medical Sciences</contact_name>
        <contact_address>Hezarjarib avenue,Isfahan,Iran. Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
